Efficacy and Safety of Dose-Escalated Alectinib in Patients With Metastatic ALK-Positive NSCLC and Central Nervous System Relapse on Standard-Dose Alectinib

This publication has 21 references indexed in Scilit:

• Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors
  Journal of Thoracic Oncology, 2020
• Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET–Rearranged Lung Cancers
  Journal of Thoracic Oncology, 2018
• Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
  The Lancet Oncology, 2017
• Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
  New England Journal of Medicine, 2017
• Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer Relapsing on Standard Dose Alectinib
  Journal of Thoracic Oncology, 2016
• Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
  The Lancet Oncology, 2014
• Survival of Patients with Non-Small-Cell Lung Cancer after a Diagnosis of Brain Metastases
  Current Oncology, 2013
• Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
  The Lancet Oncology, 2012
• Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
  Journal of Clinical Oncology, 2009
• Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
  Nature, 2007